Article ID Journal Published Year Pages File Type
8485740 Vaccine 2018 8 Pages PDF
Abstract
HBsAg-1018 had a similar safety profile to HBsAg-Eng. With improved immunogenicity and fewer doses over a shorter time, HBsAg-1018 has the potential to provide improved seroprotection and a significant public health benefit to adults 18 years of age or older.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Immunology
Preview
Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults
Authors
, , , , ,